Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Go back to Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease| (NASDAQ: IONS) | Delayed: 55.87 +1.86 (3.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.01 | 52 Week High | $62.68 | |||
| Open | $53.71 | 52 Week Low | $19.59 | |||
| Day High | $57.48 | P/E | N/A | |||
| Day Low | $53.35 | EPS | $0.00 | |||
| Volume | 3,837,426 | |||||
